SEASTAR MEDICAL HOLDING CORP

Company Overview

SeaStar Medical is a commercial-stage therapeutic medical device company that develops the Selective Cytopheretic Device (SCD), an extracorporeal, membrane‑based therapy to immunomodulate activated neutrophils/monocytes and blunt hyperinflammation. Its first product, QUELIMMUNE, launched under an FDA Humanitarian Device Exemption for pediatric AKI with initial shipments in July 2024 and a small number of active sites; an adult pivotal trial (NEUTRALIZE‑AKI / SCD‑006, 200 patients) is underway with topline/PMA timing targeted in 2026. The company has four FDA Breakthrough Device designations for additional adult/chronic indications, key supplier concentration (Fresenius for cartridges) and operational dependencies on hospitals’ RCA protocols and citrate/calcium IV supplies. SeaStar is small (≈19 FTEs end‑2024), has very limited near‑term revenue, and faces material capital‑raising and manufacturing‑scale risks.

Executive Compensation Practices

Compensation at SeaStar is likely to be equity‑heavy and milestone‑oriented given the company’s early commercial footprint, limited cash runway, and heavy R&D/clinical spend; the MD&A notes increased payroll and equity awards contributed to higher operating costs in 2024. Management has deployed pay flexibility (e.g., employees and directors rescinded unpaid bonuses/fees in 2025) and reduced cash G&A, which suggests a willingness to substitute equity or contingent payments for cash in tight liquidity periods. Key performance levers that should drive incentive design are clinical enrollment and trial milestones (e.g., NEUTRALIZE‑AKI enrollment and topline), regulatory milestones (PMA filing/approval), pediatric/commercial adoption and reimbursement outcomes, and critical supplier/manufacturing scale milestones. Fair‑value accounting for convertible instruments, warrants and share‑based awards can produce large non‑cash swings in reported compensation expense, so reported executive pay volatility may not reflect cash compensation flows.

Insider Trading Considerations

Insider activity is likely to cluster around discrete, high‑impact events: enrollment and interim/readout milestones in the adult pivotal trial, PMA filing/approval, pediatric commercial rollouts and CMS/private payer reimbursement news, and material supply or manufacturing announcements (e.g., changes to the Fresenius arrangement or secondary sourcing). Financing events (shelf takedowns, ATM sales, SEPA financings, convertible/warrant restructurings) are also major catalysts for insider transactions—both option exercises and Form 4 sales—because the company repeatedly signals funding needs and has used equity instruments to raise capital. Regulatory and market constraints (SEC disclosure rules, typical biotech blackout periods, and the use of 10b5‑1 plans) will govern timing; given the company’s going‑concern disclosures and high dilution risk, monitor insider purchases or sales for signals about insiders’ views on valuation and near‑term capital plans.